Abeona Therapeutics Inc (ABEO)vsModerna Inc (MRNA)
ABEO
Abeona Therapeutics Inc
$5.42
-1.19%
HEALTHCARE · Cap: $331.10M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 8630% more annual revenue ($2.23B vs $25.52M). MRNA leads profitability with a -141.4% profit margin vs -246.4%. ABEO earns a higher WallStSmart Score of 32/100 (F).
ABEO
Avoid32
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABEO.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 46 in profit
Revenue surging 2745.0% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABEO
The strongest argument for ABEO centers on Return on Equity, Revenue Growth, Debt/Equity. Revenue growth of 2745.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ABEO
The primary concerns for ABEO are EPS Growth, Market Cap, Free Cash Flow.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ABEO profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
ABEO carries more volatility with a beta of 1.32 — expect wider price swings.
ABEO is growing revenue faster at 2745.0% — sustainability is the question.
ABEO generates stronger free cash flow (-18M), providing more financial flexibility.
Bottom Line
ABEO scores higher overall (32/100 vs 21/100) and 2745.0% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abeona Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?